PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 24, 2006Neurology273 citations

MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy

View Full Paper
WPWhitney B. PopeALAlbert LaiPNPhioanh L. Nghiemphu

Key Points

Key points are not available for this paper at this time.

Abstract

Patients with recurrent gliomas (n = 14) were treated with bevacizumab and carboplatin, cpt-11, or etoposide. Follow-up MRI scans were obtained 2 to 6 weeks after initiation of treatment. Contrast-enhancing tumor shrank in 7 patients, with reductions evident in as little as 2 weeks after initiation of therapy. Treatment seemed more effective for heterogeneously enhancing tumor compared with solidly enhancing tumor.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Pope et al. (2006) studied this question.

synapsesocial.com/papers/6a17f1ded990e918e6b4b66chttps://doi.org/10.1212/01.wnl.0000208958.29600.87
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Dynamic Contrast-Enhanced and Diffusion MRI Show Rapid and Dramatic Changes in Tumor Microenvironment in Response to Inhibition of HIF-1α Using PX-4782005 · 130 citations
  2. 2Anti-VEGF antibody bevacizumab (Avastin) with 5FU/LV as third line treatment for colorectal cancer2004 · 40 citations
  3. 3A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse2000 · 941 citations
  4. 4Antibody neutralization of vascular endothelial growth factor (VEGF) fails to attenuate vascular permeability and brain edema in experimental pneumococcal meningitis2005 · 23 citations
  5. 5Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis2004 · 3,023 citations